Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Phys Chem Chem Phys ; 23(6): 3993-4006, 2021 Feb 19.
Artigo em Inglês | MEDLINE | ID: mdl-33554986

RESUMO

The activation of GABAA receptors by the neurotransmitter gamma-aminobutyric acid mediates the rapid inhibition response in the central nervous system of mammals. Many neurological and mental health disorders arise from alterations in the structure or function of these pentameric ion channels. GABAA receptors are targets for numerous drugs, including benzodiazepines, which bind to α1ß2γ2 GABAA receptors with high affinity to a site in the extracellular domain, between subunits α1 and γ2. It has been established experimentally that the binding of these drugs depends on the presence of one particular amino acid in the α1 subunit: histidine 102. However, the specific role it plays in the intermolecular interaction has not been elucidated. In this work, we applied in silico methods to understand whether certain protonation and rotamer states of α1His102 facilitate the binding of modulators. We analysed diazepam binding, a benzodiazepine, and the antagonist flumazenil to the GABAA receptor using molecular dynamics simulations and adaptive biasing force simulations. The binding free energy follows changes in the protonation state for both ligands, and rotameric states of α1His102 were specific for the different compounds, suggesting distinct preferences for positive allosteric modulators and antagonists. Moreover, in the presence of diazepam and favoured by a neutral tautomer, we identified a water molecule that links loops A, B, and C and may be relevant to the modulation mechanism.


Assuntos
Diazepam/metabolismo , Flumazenil/metabolismo , Moduladores GABAérgicos/metabolismo , Antagonistas de Receptores de GABA-A/metabolismo , Receptores de GABA-A/metabolismo , Histidina/química , Humanos , Simulação de Dinâmica Molecular , Conformação Proteica , Subunidades Proteicas/química , Subunidades Proteicas/metabolismo , Prótons , Receptores de GABA-A/química
2.
Stereotact Funct Neurosurg ; 97(4): 232-240, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31722358

RESUMO

BACKGROUND: Positron emission tomography (PET) imaging in epilepsy is an in vivo technique that allows the localization of a possible seizure onset zone (SOZ) during the interictal period. Stereo-electro-encephalography (SEEG) is the gold standard to define the SOZ. The objective of this research was to evaluate the accuracy of PET imaging in localizing the site of SOZ compared with SEEG. METHODS: Seven patients with refractory temporal lobe epilepsy (Ep) and 2 healthy controls (HC) underwent 2 PET scans, one with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) and another with 2'-[18F]fluoroflumazenil (FFMZ), acquired 1 day apart. FDG was acquired for 10 min (static scan) 1 h after administration. An FFMZ scan was acquired for 60 min from radiopharmaceutical administration in a dynamic mode. Each brain PET image was segmented using a standard template implemented in PMOD 3.8. The pons was used as the reference region for modeling of the nondisplaceable binding potential (BPND)for FFMZ, and to obtain uptake ratios for FDG. SEEG studies of patients were performed as a part of their surgical evaluation to define the SOZ. RESULTS: Well-defined differences between HC and Ep were found with both radiopharmaceuticals, showing the utility to identify abnormal brain regions using quantitative PET imaging. Lateralization of the SOZ findings by PET (lower uptake/binding in a specific brain hemisphere) matched in 86% for FFMZ and 71% for FDG with SEEG data. CONCLUSION: Quantitative PET imaging is an excellent complementary tool that matches reasonably well with SEEG to define SOZ in presurgical evaluation.


Assuntos
Epilepsia Resistente a Medicamentos/diagnóstico por imagem , Epilepsia do Lobo Temporal/diagnóstico por imagem , Flumazenil/análogos & derivados , Radioisótopos de Flúor , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons/métodos , Adolescente , Adulto , Mapeamento Encefálico/métodos , Epilepsia Resistente a Medicamentos/metabolismo , Epilepsia Resistente a Medicamentos/cirurgia , Epilepsia do Lobo Temporal/metabolismo , Epilepsia do Lobo Temporal/cirurgia , Feminino , Flumazenil/metabolismo , Radioisótopos de Flúor/metabolismo , Fluordesoxiglucose F18/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Convulsões/diagnóstico por imagem , Convulsões/metabolismo , Convulsões/cirurgia
3.
Pediatría (Bogotá) ; 4(1): 7-20, mar. 1994. tab
Artigo em Espanhol | LILACS | ID: lil-190488

RESUMO

Los antídotos son sustancias cuya función es contrarrestar el efecto farmacológico y tóxico de otras sustancias, teniendo en cuenta la importancia de las medidas generales en el manejo del intoxicado (baño general, emesis, lavado gástrico, carbón activado, catárticos). Cada día aparecen sustancias nuevas con dichas características. En el presente artículo se pretende dar información breve y detallada sobre las propiedades farmacológicas, indicaciones, dosificación, efectos secundarios y contraindicaciones de algunos de uso general (carbón activado, soluciones electrolíticas con polietilenglycol) y principalmente de algunos específicos de uso reciente: flumazenil, fragmentos Fab-antidigoxina, glucagón, naloxona, clonidina, N-acetil-cisteína, azul de metileno, nitrito y tiosulfato de sodio, ácido-2-3-dimercaptosuccínico, penicilina benzatínica, glicopirrolato y S-adenosil-metionina.


Assuntos
Humanos , Antídotos/administração & dosagem , Antídotos/classificação , Antídotos/farmacologia , Antídotos/toxicidade , Antídotos , Antídotos/uso terapêutico , Carvão Vegetal , Flumazenil , Flumazenil/administração & dosagem , Flumazenil/agonistas , Flumazenil/antagonistas & inibidores , Flumazenil/metabolismo , Flumazenil/farmacocinética , Flumazenil/farmacologia , Flumazenil/uso terapêutico , Flumazenil/toxicidade , Glucagon , Glucagon/administração & dosagem , Glucagon/agonistas , Glucagon/antagonistas & inibidores , Glucagon/farmacocinética , Glucagon/uso terapêutico , Glucagon/toxicidade , Naloxona , Naloxona/administração & dosagem , Naloxona/agonistas , Naloxona/antagonistas & inibidores , Naloxona/farmacocinética , Naloxona/uso terapêutico
4.
Neurochem Res ; 16(1): 57-62, 1991 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1646969

RESUMO

To investigate the interaction between gamma-aminobutyric acid (GABA) and benzodiazepine (BZD) receptor sites during development, the time-course of appearance of flunitrazepam (FNZ) binding sites and their pharmacological characterization were studied in developing chick optic lobe. At the earliest stage examined, embryonic day (Ed) 12, the receptor density was 30.9% (0.05 +/- 0.01 pmol/mg protein) of that found in the chick optic lobes of adult chicks. The adult value was achieved on Ed 16 (0.16 +/- 0.01 pmol/mg protein). After this stage there was a sharp and transient increase in specific [3H]FNZ binding of about two-fold reaching a maximal value between hatching and the postnatal day (pnd) 2 (0.33 +/- 0.01 pmol/mg protein). Scatchard analysis at different stages of development revealed the presence of a single population of specific FNZ binding sites. The increase in [3H]FNZ binding during development was due to a large number of binding sites while their affinity remained unchanged. Competition experiments in the chick optic lobe revealed that the order of potency for displacement of specific [3H]FNZ binding paralleled the pharmacological potency of the BZDs tested. The IC50s for clonazepam, flunitrazepam, Ro 15-1788 and chlordiazepoxide were 3.02, 4.30, 0.32, and 4778.64 nM respectively. Ro 5-4864, a potent inhibitor of BZD binding to peripheral tissues, had no effect on specific [3H]FNZ binding indicating that only central BZD binding sites are present in the chick optic lobe. The peak of maximal expression of BZD receptor sites precedes in 5-6 days the peak of GABA receptor sites indicating a precocious development of BZD receptor sites.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Receptores de GABA-A/metabolismo , Teto do Mesencéfalo/crescimento & desenvolvimento , Animais , Ligação Competitiva , Embrião de Galinha , Galinhas , Clonazepam/metabolismo , Flumazenil/metabolismo , Flunitrazepam/metabolismo , Cinética , Receptores de GABA-A/efeitos dos fármacos , Membranas Sinápticas/metabolismo , Teto do Mesencéfalo/embriologia , Teto do Mesencéfalo/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA